New hope for kids with brain cancer? LAM561 trial launches
NCT ID NCT04299191
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an oral drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose in up to 18 children, then testing that dose in another 10 children to confirm safety. The goal is to see if LAM561 can control the disease and to determine the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAM561 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat brain tumors.
What could go wrong
This is an early-phase trial with only 28 participants, so the drug may not prove effective or may have side effects. It is not a cure and long-term benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Research Institute
RECRUITINGLittle Rock, Arkansas, 72202, United States
Contact Email: •••••@•••••
Contact
-
Hackensack Meridian Health, Inc
RECRUITINGEdison, New Jersey, 08837, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami Hospital
RECRUITINGMiami, Florida, 33146, United States
Contact